Your browser doesn't support javascript.
loading
Mimicking and surpassing the xenograft model with cancer-on-chip technology.
Komen, Job; van Neerven, Sanne M; van den Berg, Albert; Vermeulen, Louis; van der Meer, Andries D.
Affiliation
  • Komen J; BIOS Lab on a Chip group, MESA+ Institute for Nanotechnology, University of Twente, P. O. Box 217, 7500 AE Enschede, the Netherlands. Electronic address: j.komen@utwente.nl.
  • van Neerven SM; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, 1105 AZ, Amsterdam, the Netherlands.
  • van den Berg A; BIOS Lab on a Chip group, MESA+ Institute for Nanotechnology, University of Twente, P. O. Box 217, 7500 AE Enschede, the Netherlands.
  • Vermeulen L; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, 1105 AZ, Amsterdam, the Netherlands.
  • van der Meer AD; Applied Stem Cell Technologies, TechMed Centre, University of Twente, P. O. Box 217, 7500 AE Enschede, the Netherlands.
EBioMedicine ; 66: 103303, 2021 Apr.
Article in En | MEDLINE | ID: mdl-33773183
Organs-on-chips are in vitro models in which human tissues are cultured in microfluidic compartments with a controlled, dynamic micro-environment. Specific organs-on-chips are being developed to mimic human tumors, but the validation of such 'cancer-on-chip' models for use in drug development is hampered by the complexity and variability of human tumors. An important step towards validation of cancer-on-chip technology could be to first mimic cancer xenograft models, which share multiple characteristics with human cancers but are significantly less complex. Here we review the relevant biological characteristics of a xenograft tumor and show that organ-on-chip technology is capable of mimicking many of these aspects. Actual comparisons between on-chip tumor growth and xenografts are promising but also demonstrate that further development and empirical validation is still needed. Validation of cancer-on-chip models to xenografts would not only represent an important milestone towards acceptance of cancer-on-chip technology, but could also improve drug discovery, personalized cancer medicine, and reduce animal testing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomimetics / Disease Models, Animal / Lab-On-A-Chip Devices / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: EBioMedicine Year: 2021 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomimetics / Disease Models, Animal / Lab-On-A-Chip Devices / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: EBioMedicine Year: 2021 Document type: Article Country of publication: